Literature DB >> 19058322

Function of the hemochromatosis protein HFE: Lessons from animal models.

Kostas Pantopoulos.   

Abstract

Hereditary hemochromatosis (HH) is caused by chronic hyperabsorption of dietary iron. Progressive accumulation of excess iron within tissue parenchymal cells may lead to severe organ damage. The most prevalent type of HH is linked to mutations in the HFE gene, encoding an atypical major histocompatibility complex class I molecule. Shortly after its discovery in 1996, the hemochromatosis protein HFE was shown to physically interact with transferrin receptor 1 (TfR1) and impair the uptake of transferrin-bound iron in cells. However, these findings provided no clue why HFE mutations associate with systemic iron overload. It was later established that all forms of HH result from misregulation of hepcidin expression. This liver-derived circulating peptide hormone controls iron efflux from duodenal enterocytes and reticuloendothelial macrophages by promoting the degradation of the iron exporter ferroportin. Recent studies with animal models of HH uncover a crucial role of HFE as a hepatocyte iron sensor and upstream regulator of hepcidin. Thus, hepatocyte HFE is indispensable for signaling to hepcidin, presumably as a constituent of a larger iron-sensing complex. A working model postulates that the signaling activity of HFE is silenced when the protein is bound to TfR1. An increase in the iron saturation of plasma transferrin leads to displacement of TfR1 from HFE and assembly of the putative iron-sensing complex. In this way, iron uptake by the hepatocyte is translated into upregulation of hepcidin, reinforcing the concept that the liver is the major regulatory site for systemic iron homeostasis, and not merely an iron storage depot.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058322      PMCID: PMC2773850          DOI: 10.3748/wjg.14.6893

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  119 in total

1.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

Review 2.  Iron, hemochromatosis, and hepatocellular carcinoma.

Authors:  Kris V Kowdley
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

3.  Duodenal ferritin synthesis in genetic hemochromatosis.

Authors:  A Pietrangelo; G Casalgrandi; D Quaglino; R Gualdi; D Conte; S Milani; G Montosi; L Cesarini; E Ventura; G Cairo
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

4.  Increased hepcidin expression and hypoferraemia associated with an acute phase response are not affected by inactivation of HFE.

Authors:  David M Frazer; Sarah J Wilkins; Kirstin N Millard; Andrew T McKie; Christopher D Vulpe; Gregory J Anderson
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

5.  beta2 knockout mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism.

Authors:  B E Rothenberg; J R Voland
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

6.  The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes.

Authors:  Pauline Lee; Hongfan Peng; Terri Gelbart; Ernest Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

7.  Regulation of transferrin, transferrin receptor, and ferritin genes in human duodenum.

Authors:  A Pietrangelo; E Rocchi; G Casalgrandi; G Rigo; A Ferrari; M Perini; E Ventura; G Cairo
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

8.  Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis.

Authors:  Darrell H G Crawford; Linda M Fletcher; Stefan G Hubscher; Katherine A Stuart; Edward Gane; Peter W Angus; Gary P Jeffrey; Geoffrey W McCaughan; Paul Kerlin; Lawrie W Powell; Elwyn E Elias
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

9.  Iron overload in beta 2-microglobulin-deficient mice.

Authors:  M de Sousa; R Reimão; R Lacerda; P Hugo; S H Kaufmann; G Porto
Journal:  Immunol Lett       Date:  1994-02       Impact factor: 3.685

10.  Expression of the hereditary hemochromatosis protein HFE increases ferritin levels by inhibiting iron export in HT29 cells.

Authors:  Paige S Davies; Caroline A Enns
Journal:  J Biol Chem       Date:  2004-03-25       Impact factor: 5.157

View more
  18 in total

1.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

2.  Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration.

Authors:  Se Na Moon; Ji Whan Han; Hui Seung Hwang; Mee Jeong Kim; Soon Ju Lee; Jae Young Lee; Chang Kyu Oh; Dae Chul Jeong
Journal:  Pediatr Cardiol       Date:  2011-06-09       Impact factor: 1.655

3.  [Osteoarthritis in hereditary metabolic diseases].

Authors:  J Zwerina; T Dallos
Journal:  Orthopade       Date:  2010-06       Impact factor: 1.087

Review 4.  [Osteoarthritis in hereditary metabolic diseases].

Authors:  J Zwerina; T Dallos
Journal:  Z Rheumatol       Date:  2010-05       Impact factor: 1.372

5.  Transferrin and H-ferritin involvement in brain iron acquisition during postnatal development: impact of sex and genotype.

Authors:  Brian Chiou; Elizabeth B Neely; Dillon S Mcdevitt; Ian A Simpson; James R Connor
Journal:  J Neurochem       Date:  2019-08-22       Impact factor: 5.372

Review 6.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

7.  Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.

Authors:  N Jaekel; K Lieder; S Albrecht; O Leismann; K Hubert; G Bug; N Kröger; U Platzbecker; M Stadler; K de Haas; S Altamura; M U Muckenthaler; D Niederwieser; H K Al-Ali
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 8.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

Review 9.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

10.  Knowledge building insights on biomarkers of arsenic toxicity to keratinocytes and melanocytes.

Authors:  Raphael D Isokpehi; Udensi K Udensi; Matthew N Anyanwu; Andreas N Mbah; Matilda O Johnson; Kafui Edusei; Michael A Bauer; Roger A Hall; Omotayo R Awofolu
Journal:  Biomark Insights       Date:  2012-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.